journal
https://read.qxmd.com/read/38601836/a-unique-delusion-with-depression-in-early-stage-of-neurocognitive-disorder-due-to-vascular-disease-considerations-for-clinicians
#1
REVIEW
Mounica Thootkur, Binx Yezhe Lin, Akhil S Pola, Alexander Zhang, Zhengshan Liu, Michael Greenage, Justin White, Mamta Sapra
As global aging becomes more prominent, neurocognitive disorders (NCD) incidence has increased. Patients with NCD usually have an impairment in one or more cognitive domains, such as attention, planning, inhibition, learning, memory, language, visual perception, and spatial or social skills. Studies indicate that 50-80% of these adults will develop neuropsychiatric symptoms (NPS), such as apathy, depression, anxiety, disinhibition, delusions, hallucinations, and aberrant motor behavior. The progression of NCD and subsequent NPS requires tremendous care from trained medical professionals and family members...
April 4, 2024: Psychopharmacology Bulletin
https://read.qxmd.com/read/38601835/clozapine-prescripers-dogmatic-or-pragmatic
#2
REVIEW
Ahmed Naguy, Hessa Alhazeem
Clozapine, amongst antipsychotics, has a unique composite mode of action that might translate into an expanded therapeutic potential on clinical grounds. Sorely, clozapine remains underutilized.
April 4, 2024: Psychopharmacology Bulletin
https://read.qxmd.com/read/38601834/efficacy-of-rivastigmine-augmentation-on-positive-and-negative-symptoms-general-psychopathology-and-quality-of-life-in-patients-with-chronic-schizophrenia-a-randomized-controlled-trial
#3
RANDOMIZED CONTROLLED TRIAL
Sepideh Herizchi, Ali Reza Shafiee-Kandjani, Mostafa Farahbakhsh, Zahra Jahangiri, Shahriyar Ghanbarzadeh Javid, Hosein Azizi
The study aimed to assess Rivastigmine augmentation on positive and negative symptoms (PNSs), general psychopathology, and quality of life in patients with chronic Schizophrenia. A double-blind, parallel-design, randomized, placebo-controlled trial of 60 schizophrenia patients was conducted. Intervention group received rivastigmine 3 mg/day + Treatment as Usual (TAU) and the control group: TAU + placebo. Negative and positive symptoms, general psychopathology; and quality of life were measured using Positive and Negative Symptom Scale (PANSS) and Manchester Short Assessment of Quality of Life (MANSA)...
April 4, 2024: Psychopharmacology Bulletin
https://read.qxmd.com/read/38601833/case-report-on-high-dose-lithium-treatment-for-post-covid-depression-recurrent-fevers-and-skin-lesions
#4
Lila Elizabeth Massoumi, Alan Rosenbaum
This is a case of a 35-year-old woman who presented with an 18-month history of post (long)-COVID depression and exhaustion along with recurrent fevers and treatment-resistant skin boils, all of which abated with lithium treatment at a serum level of 1.14 mmol/L, and all of which worsened when the lithium serum level was lowered to 0.8. This paper illustrates Lithium's effectiveness in the treatment of post (long)-COVID syndrome, though a higher serum concentration may be required.
April 4, 2024: Psychopharmacology Bulletin
https://read.qxmd.com/read/38601832/zolpidem-stimulant-effect-and-dependence-a-case-report-on-intranasal-use
#5
Branimir Margetić, Marina Alaber
Zolpidem is a widely used hypnotic. Dependence on zolpidem due to the induction of euphoria is a rare condition, while intranasal misuse of zolpidem is a rather new phenomenon. We present the first case of a patient who developed zolpidem dependence, which was associated with the prompt onset of euphoria exclusively following intranasal use. Mr. A was a 51-year-old polydrug abuser with antisocial personality disorder and a physical dependence on zolpidem. Over several years, he consumed 500 mg of the drug daily, usually divided into 30 mg doses, exclusively via the nasal route because unlike the oral administration of the same dose of the drug, intranasal administration induced euphoria...
April 4, 2024: Psychopharmacology Bulletin
https://read.qxmd.com/read/38601831/a-bell-s-palsy-case-probably-related-to-sertraline-use
#6
JOURNAL ARTICLE
Mehmet Emin Ceylan, Barış Önen Ünsalver, Hatice Zeynep Ceylan
No abstract text is available yet for this article.
April 4, 2024: Psychopharmacology Bulletin
https://read.qxmd.com/read/38601830/clavulanic-acid-decreases-cocaine-cue-reactivity-in-addiction-related-brain-areas-a-randomized-fmri-pilot-study
#7
JOURNAL ARTICLE
Linda S Callans, Helene Philogene-Khalid, Kanchana Jagannathan, Ronan Cunningham, Daohai Yu, Xiaoning Lu, M Ingre Walters, Mary F Morrison
BACKGROUND: Preclinical studies show that clavulanic acid (CLAV) inhibits cocaine self-administration. This study investigates the effect of CLAV on regions of brain activation in response to cocaine cues during functional magnetic resonance imaging (fMRI) in participants with cocaine use disorder (CUD). METHODS: A double-masked, placebo-controlled clinical trial with thirteen individuals with severe CUD who were randomized to treatment with CLAV (N = 10, 9 completers) 500 mg/day or matched placebo (PBO) (N = 3) for 3 days...
April 4, 2024: Psychopharmacology Bulletin
https://read.qxmd.com/read/38601829/correction
#8
(no author information available yet)
[This corrects the article , PMID: 37601085.].
April 4, 2024: Psychopharmacology Bulletin
https://read.qxmd.com/read/38449476/pregabalin-adjuventia-helped-risperidone-induced-extrapyramidal-syndrome-and-augmented-antipsychotic-response-in-an-adolescent-with-schizophrenia
#9
Ahmed Naguy, Saxby Pridmore, Bibi Alamiri
Here, authors report on an interesting case of early-onset of schizophrenia where adjunctive pregabalin alleviated risperidone-induced pseudoparkinsonism, helped with insomnia and agitation and boosted antipsychotic response with great tolerability. We wager that gabapentenoids can be a viable option in the niche of psychopharmacotherapy of schizophrenia in CAP population.
March 4, 2024: Psychopharmacology Bulletin
https://read.qxmd.com/read/38449475/a-comprehensive-review-of-lemborexant-to-treat-insomnia
#10
REVIEW
Mitchell C Fuller, Samuel F Carlson, Chris Grant, Vince Berry, Marko Ivancich, Elyse M Cornett, Adam M Kaye, Omar Viswanath, Ivan Urits, Sahar Shekoohi, Alan D Kaye
PURPOSE OF REVIEW: This is a comprehensive review of the literature regarding Lemborexant for the treatment of insomnia. It covers the background and management of insomnia and then reviews the body of existing evidence evaluating the use of Lemborexant for this purpose. RECENT FINDINGS: Insomnia leads to significant decreased in quality of life and economic burden due to decreased workplace performance and increased health care costs. Insomnia manifests as a single common pathway of hyperarousal due to a highly complex network of interactions between activation of the sympathetic system and the endocrine system...
March 4, 2024: Psychopharmacology Bulletin
https://read.qxmd.com/read/38449474/new-onset-prolonged-psychosis-following-synthetic-cannabinoid-use-in-an-older-patient-a-case-report
#11
Ahmed Alhassan, Srihari R Prahad, Bradley G Burk, Rachel E Fargason, Badari Birur
Synthetic cannabinoids (SCs), a class of new psychoactive substances (NPS) commonly known as "spice," has rapidly gained popularity and become the most ubiquitous NPS on the illegitimate drug market. SCs, unlike natural cannabis (NC), are not controlled by international drug conventions, posing a significant risk to public health. These substances are easily accessible, relatively inexpensive, and challenging to detect in routine drug screenings. The existing literature provides strong evidence of an association between NC use and psychosis, but there is significantly less data on SC psychosis...
March 4, 2024: Psychopharmacology Bulletin
https://read.qxmd.com/read/38449473/duration-of-untreated-illness-in-obsessive-compulsive-disorder-and-its-associated-factors
#12
REVIEW
Anas Ibn Auf, Abdelgadir Osman
INTRODUCTION: The period before effective treatment is administered, is known as the duration of untreated illness (DUI). It has been found to relate to prognoses and sensitivity to treatment. The DUI is yet to be fully investigated in relation to obsessive-compulsive disorder (OCD). METHOD: The present study examined a sample of 89 patients who presented with OCD over a span of two years and who were treated at a clinic in Khartoum, the capital city of Sudan. We examined the mean DUI before the patients received an effective psychiatric intervention...
March 4, 2024: Psychopharmacology Bulletin
https://read.qxmd.com/read/38449472/a-phase-2-open-label-study-of-efficacy-safety-and-tolerability-of-sls-002-intranasal-racemic-ketamine-in-adults-with-mdd-at-imminent-risk-of-suicide
#13
JOURNAL ARTICLE
Timothy Whitaker, Kimberly F Farrand, Michael E Thase
BACKGROUND: Despite the prevalence of Major Depressive Disorder (MDD) and the propensity of affected individuals to eventually die by suicide, there is no therapeutic approved specifically for suicidal ideation and behavior (SI/B) in MDD. The NMDA receptor antagonist ketamine has been investigated for the treatment of depression and shown to have a rapid effect on symptoms. Spravato® (esketamine) is approved by the FDA for use in treatment-resistant depression and Major Depressive Episodes with Suicidal Ideation based on studies conducted in adults also taking standard antidepressants...
March 4, 2024: Psychopharmacology Bulletin
https://read.qxmd.com/read/38449471/a-comprehensive-review-of-solriamfetol-to-treat-excessive-daytime-sleepiness
#14
REVIEW
Mitchell C Fuller, Samuel Carlson, Haley Pysick, Vince Berry, Andrew Tondryk, Hayden Swartz, Elyse M Cornett, Adam M Kaye, Omar Viswanath, Ivan Urits, Alan D Kaye
PURPOSE OF REVIEW: This is a comprehensive review of the literature regarding the use of Solriamfetol for excessive daytime sleepiness. It covers the background and current therapeutic approaches to treating excessive daytime sleepiness, the management of common comorbidities, and the existing evidence investigating the use of Solriamfetol for this purpose. RECENT FINDINGS: Excessive daytime sleepiness leads to worse quality of life, a medical sequela and significant economic cost...
March 4, 2024: Psychopharmacology Bulletin
https://read.qxmd.com/read/38449470/a-pilot-study-to-explore-the-effect-of-long-acting-injectable-antipsychotics-on-aggression
#15
JOURNAL ARTICLE
Tiffany M Hopkins, O Greg Deardorff, Yifei Liu, Megan G Trout, Roger W Sommi, Niels C Beck
OBJECTIVES: To explore the effect of switching from an oral antipsychotic to a long-acting injectable (LAI) antipsychotic on aggression, in terms of the changes of verbal and physical aggression, interventions required, self-injurious behavior, use of seclusion or restraint, antipsychotic medication refusal, and use of antipsychotics as needed (PRN). METHODS: This was a retrospective chart review at a long-term state forensic psychiatric facility. Patients treated with an oral antipsychotic for at least 6 months and then switched to a LAI antipsychotic for an additional 6 months during an 80-month period were included...
March 4, 2024: Psychopharmacology Bulletin
https://read.qxmd.com/read/38076669/association-of-psychopharmacological-medication-preference-with-autistic-traits-and-emotion-regulation-in-adhd
#16
JOURNAL ARTICLE
Burcu Ozbaran, Ipek Inal-Kaleli, Nurhak Dogan, Halil Ibrahim Colak, Anil Altunkaya, Beyza Ozbaran, Sezen Kose
BACKGROUND: This study intends to evaluate the relationship between medication switching and autistic traits, emotion dysregulation, and methylphenidate side effects in children with attention deficit hyperactivity disorder (ADHD). METHODS: Children with ADHD, ages 9-18, treated with methylphenidate (MTP) (n = 23), and switched to atomoxetine (ATX) (n = 20) were included. All participants were interviewed with K-SADS-PL to confirm ADHD diagnosis and exclude comorbid psychiatric disorders...
December 4, 2023: Psychopharmacology Bulletin
https://read.qxmd.com/read/38076668/relationship-of-cyp3a4-1b-single-nucleotide-polymorphism-to-the-efficiency-and-safety-profiles-of-haloperidol-in-patients-enduring-acute-alcoholic-hallucinosis
#17
JOURNAL ARTICLE
A A Parkhomenko, M S Zastrozhin, VYu Skryabin, A E Petukhov, S A Pozdniakov, V A Ivanchenko, I A Zaytsev, I V Bure, P O Bochkov, K A Akmalova, V V Smirnov, E A Bryun, D A Sychev
UNLABELLED: To date, haloperidol has been widely used to treat patients with acute alcoholic hallucinosis. There is strong evidence that haloperidol therapy is commonly associated with adverse drug reactions (ADRs). The 392A > G polymorphism of the CYP3A4 * 1B gene (rs2740574) is known to affect the metabolism rates of haloperidol; hence it correlates with both therapy efficacy and safety parameters. OBJECTIVE: The study objective was to investigate the effect of 392A > G polymorphism of the CYP3A4 * 1B gene (rs2740574) on the efficacy and safety profiles of haloperidol in patients with acute alcoholic hallucinosis...
December 4, 2023: Psychopharmacology Bulletin
https://read.qxmd.com/read/38076667/consequences-of-1-4-butanediol-misuse-a-review
#18
REVIEW
VYu Skryabin, YuB Shevtsova, E A Novoselova
Gamma-hydroxybutyrate (GHB), along with its precursors, 1,4-butanediol (1,4-BD) and gamma-butyrolactone (GBL), are potent central depressant agents widely illicitly used for their euphoric and relaxant effects. The article presents a review of the literature on the 1,4-BD misuse, the clinical picture of intoxication, development of addiction and delirium. The available evidence shows that 1,4-BD is a substance with its own psychoactive effects, a high addiction potential and potentially severe withdrawal symptoms...
December 4, 2023: Psychopharmacology Bulletin
https://read.qxmd.com/read/38076666/%C3%AE-blockers-for-autism-help-or-hindrance
#19
REVIEW
Ahmed Naguy, Seshni Gourika Moodliar-Rensburg, Bibi Alamiri
A renewed interest in the use of β-blockers for neurodevelopmental disorders has recently resurfaced, notably as an addition to the limited psychopharmacological armamentarium of autism spectrum disorders (ASD). In this clinical perspective, authors decently argue this use could be advantageous and multi-folded for this population.
December 4, 2023: Psychopharmacology Bulletin
https://read.qxmd.com/read/38076665/rhabdomyolysis-complicated-with-hyponatremia-due-to-water-intoxication-and-severe-aspiration-pneumonia-description-of-a-patient-with-chronic-schizophrenia-and-literature-review
#20
REVIEW
Shintaro Watanabe, Yoshio Sato, Junya Miyaki, Takefumi Suzuki
Hyponatremia due to water intoxication is frequently observed in patients with chronic schizophrenia. We herein present a 49-year-old man who developed schizophrenia at the age of 23 and had been admitted to the closed ward of our hospital for 7 years. He was found by a round nurse standing at the bedside, covering both ears with his hands and making groaning noises. He was disoriented and immediately after being returned to bed, a general tonic-clonic seizure occurred. Severe hyponatremia (Na 104 mEq/L) was noted and intravenous sodium correction was started...
December 4, 2023: Psychopharmacology Bulletin
journal
journal
21610
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.